Inverness Medical Innovations Inc. (NYSE:IMA) agreed to pay $110 million in cash for Marsh & McLennan Cos. Inc. (NYSE: MMC) subsidiary Kroll Inc.’s substance abuse testing lab.
It’s the latest in a series of strategic moves for the Waltham, Mass.-based diagnostics and lab equipment maker, which has been on a buying (and selling) spree so far this year.